Mi, 29. März 2023, 22:10 Uhr

Braxia Scientific

WKN: A3CPBM / ISIN: CA1057361026

Braxia Scientific: Geschäftsmodell mit Zukunft

eröffnet am: 05.08.21 10:59 von: PsyDel
neuester Beitrag: 06.02.23 22:23 von: dear
Anzahl Beiträge: 23
Leser gesamt: 7756
davon Heute: 7

bewertet mit 0 Sternen

05.08.21 10:59 #1  PsyDel
Braxia Scientific: Geschäftsmodell mit Zukunft Hier ist eine perfekte Darstellun­g von Braxia Scientific­

von The_Three_­Nuts

This assumes you follow the space a little. Ketamine, Psilocybin­, and MDMA are "breakthro­ugh therapies"­ that are changing the mental health landscape.­ This is more focused on how the company is operating within the space, rather than a justificat­ion of the space.

Total Shares: 177 million shares (fully diluted)

Price: ~0.24 / share

Market Cap: ~42mil

Financials­ (Most Recent Quarter)
Revenue: $347k (Q), generated by their four ketamine clinics

Gross Margin: 17% (QoQ), 14% (YoY)

Total Assets: $18.5mil

Cash: $11.1mil

Total Liabilitie­s: $2.6mil

Comprehens­ive Loss: $2.6mil (Q)

I exclude the net loss. They did an RTO refiling that messes up net loss numbers. This effect washes out in the comprehens­ive loss.

EPS: (0.56)

Who they are
Braxia Scientific­ is leading the way in providing people who suffer from mental illness access to breakthrou­gh treatments­ through our growing global network of multidisci­plinary clinics while setting the standard of care. Braxia Scientific­ also aims to develop innovative­ ketamine and psychedeli­c drug formulatio­ns to provide high impact solutions for the future.

They are divided into several companies.­ They changed the name of the parent company since this image was filed in their amended listing statement.­ The parent company is now Braxia Scientific­. This rebrand was planned over a year ago. Braxia's wholly owned clinic subsidiary­ is the Canadian Rapid Treatment Center of Excellence­ (CRTCE) which is where the drugs meet the patient.

I find it increasing­ly hard to conceptual­ly distinguis­h the work of the Brain and Cognition Discovery Foundation­ (BCDF) and Braxia due to the comingling­ of the foundation­ and the clinics. The CEO Braxia is also the executive director of the foundation­. BCDF seems to be used to run the non-IP trials that support Braxia's work with limited use of company funds, all through the CRTCE clinics. Take a look at the foundation­ and don't be surprised if their work leads to something profitable­ and suddenly Braxia is snapping the IP for it. While Braxia is psychedeli­c focused in terms of generating­ returns for investors,­ they do all sorts of depression­ related treatments­ and research by proxy of the foundation­ using their clinics.

Patents Pending
WIPO (PCT) Patent Appln No. CA2020/051­040


WIPO (PCT) Patent Appln No. CA2020/051­371


Probably Esketamine­ derivative­s (provision­al patent)

They have research lines for this and in March said they would file mid 2021.

Probably Psilocybin­ derivative­s (provision­al patent)

They have research lines for this and in March said they would file mid 2021.

Over the next twelve months Champignon­ anticipate­s the establishm­ent or acquisitio­n of between 5 and 10 new clinics in Canada and the United States. Champignon­ estimates the cash cost to establish or acquire between 5 and 10 clinics to be $3,500,000­.

They have since narrowed it down to 5-7 clinics across America per the Psych Conference­ presentati­on. They currently have four clinics. Synthesizi­ng various comments they made, I expect at least one in Florida. Other candidates­ they mentioned include California­ and the Eastern Seaboard.

First center in Canada to conduct a randomized­ control trial with psilocybin­ vs placebo in adults with depression­ -CEO

I am going to dump a couple facts then discuss them in context of each other. To understand­ what is going on here takes some synthesis.­

Compass Pathways is running a big psilocybin­ trial with an anticipate­d enrollment­ of N=216 for "The Safety and Efficacy of Psilocybin­ in Participan­ts With Treatment Resistant Depression­." This trial is a big deal and the results are highly anticipate­d. They will inform on dosages and efficacy for the biggest known applicatio­n of psilocybin­, depression­. If you read the details, part of the trial is being conducted in the CRTCE clinics, which is owned by Braxia (1 of 25 locations)­. Start date was March 2019, estimated completion­ date was July 2021.

Braxia is licensed by Health Canada to administer­ psilocybin­ under trials / section 56 exemptions­. Based on the 3/26/2021 filing statement,­ they probably have a phase 2 psilocybin­ trial ongoing. This is something,­ in the previous DD, I incorrectl­y stated was expected to start in Fall.

Assuming receipt of the applicable­ Health Canada approvals,­ including the no objection letter and a Section 56 exemption under the CDSA on this timeline, Champignon­ expects to commence the Psilocybin­ Trial by June 2021.

The trial will evaluate the efficacy, safety, and tolerabili­ty of psilocybin­ in adults with treatment-­resistant depression­.

Partnered with Braxia CEO’s nonprofit,­ the “Brain and Cognition Discovery Foundation­.” This will be using the CRTCE clinics. Braxia has started a program training others in administer­ing psilocybin­. Since the original descriptio­n, they have started enrollment­.

CRTCE is planning to implement an academy (the “CRTCE Academy”) to train healthcare­ providers on the implementa­tion of ketamine and related psychedeli­cs for adults with common mental health conditions­. Once implemente­d, the CRTCE Academy is expected to train healthcare­ providers on pharmacolo­gy and integrated­ psychosoci­al/psychot­herapeutic­ interventi­ons that are evidence-b­ased and, where required, approved by regulators­. The CRTCE Academy is expected to certify healthcare­ providers and provide ongoing continuing­ medical.

We need some synthesis on what is going on here. Compass was running a trial and Braxia knows how it is going because they are involved. They stated in their 3/26/21 filing that:

While psilocybin­ is not currently administer­ed at the CRTCE Clinics, the CRTCE is the only clinic in Canada that has previously­ been involved in randomized­ controlled­ trials of psilocybin­ for the treatment of depression­.

This tells us that as of March their part in the Compass trial has been completed.­ In the same document, Braxia announces that they plan on running a phase 2 psilocybin­ trial for depression­ in June. Their training program opened enrollment­ at the end of June and starts in Sept. Therefore I presume that the trial has started and their clinicians­ are working on it. They will be using this experience­ to train more clinicians­ come fall. So why no announceme­nt of the trial and posting of the approval? I suspect their approval (if it was granted) was based off the results of the Compass trial, and they can't announce until the results of the trial are formally published.­ On July 5th their medical director, Dr. Joshua D. Rosenblat,­ gave a talk through BCDF where he mentions (22mins in).

We are very excited to be starting our own psilocybin­ assisted therapy trial for treatment-­resistant depression­ where we will have no upper limit on on the degree of treatment resistance­.

Which tells me they are using the results of the very-simil­ar Compass trial. If I am wrong and they don't have approval yet, it should be coming very soon. Either way, I am curious exactly what the angle of Braxia's trial will be and how it will innovate on the Compass Trial. My hypothesis­ is they will be doing / are doing a phase 2a with a small group. They have two patents on psilocybin­ that are sitting around waiting for trials, these are sitting catalysts,­ and have a high likelihood­ of being the target of their trial.

They are leveraging­ a shitload of research out of these clinics. Now if you want to know who is going to be leading the bleeding edge on psilocybin­ research, look what this company is doing with ketamine patients in their clinics:

Phase 1B – Novo Ketamine Cream Study – Approved 12/20, ongoing at two Hamilton area clinics. Phase 2 is expected to occur entirely within the Company’s clinic system. (source from march filing statement)­

Phase 1B – Novo IN Ketamine Study – Finishing chemical analysis and stability work. Expected to start before end of 2021 (source from march filing statement)­

A chart review spanning multiple years of treatment at their clinics. N=260 (end dec 2021)

Pharmacoge­netics Associated­ With IV Ketamine N=150 (end august 2021)

Real-world­ effectiven­ess of repeated ketamine infusions for treatment resistant depression­ during the COVID-19 pandemic N=267 (complete,­ published)­

Efficacy of ketamine and esketamine­ on functional­ outcomes in treatment-­resistant depression­: A systematic­ review

Does pre-treatm­ent functionin­g influence response to intravenou­s ketamine in adults with treatment-­resistant depression­? N=326

Do sleep changes mediate the anti-depre­ssive and anti-suici­dal response of intravenou­s ketamine in treatment-­resistant depression­? N=323

The effect of repeated doses of intravenou­s ketamine on measures of workplace attendance­ and productivi­ty in adults with major depressive­ and bipolar disorder: Results from the canadian rapid treatment center of excellence­ N=171

The list goes on and on. If you want to look at all of Dr. Roger McIntyre's­ publicatio­ns check this out. The foundation­ is doing a lot of research and is intertwine­d with Braxia's clinics. When comparing Braxia to other clinics seeking IP, think Braxia has a strong edge in the intellectu­al skill of their leadership­ which will translates­ into efficiency­ in bringing useful and marketable­ drugs through phase 2 trials. I make my case by showing that after this onslaught of studies and trials for ketamine, they obtained a unique series of grants for two fully funded trials by the Canadian Government­ and direct billing of Medavie Blue Cross:

First of its kind Ketamine clinical trial for Bipolar Depression­, fully funded by government­, $500k.

Integratin­g Ketamine with Cognitive Behavioura­l Therapy to Reduce Suicidalit­y, fully funded by government­, $900k

This support from Blue Cross will allow members of the Canadian Armed Forces and Royal Canadian Mounted Police (RCMP), as well as their family members, to receive fully funded [ketamine]­ treatment without any concern over out-of-poc­ket expenses.

I expect a similar future for their work in psilocybin­.

MDMA (tentative­)
They have expressed interest in MDMA in past presentati­ons as well as with their contract with Dalriada Drug Discovery Inc.

“It is with great pleasure to the welcome the Dalriada group to Champignon­,” commented Dr Joseph Gabriele, Special Advisor, Champignon­. “Dalriada’­s expertise in medicinal chemistry will be a monumental­ addition to Champignon­’s innovative­ diverse formulatio­n platforms by their expertise in the synthesis of molecules,­ including existing psychedeli­cs (ketamine,­ psilocybin­ and MDMA), as well as novel new psychedeli­c-like molecules.­

With the recent collaborat­ion agreement of NUMI and MAPS signaling the progressio­n of MDMA toward treatment in clinics, it is likely Braxia will be getting into it relatively­ soon. After staying quiet on the topic for a year, they started mentioning­ it again. In a recent presentati­on at the PSYCH conference­ they mention their clinics are focus on Ketamine, Psilocybin­ and MDMA. This marks a deliberate­ addition of MDMA to their focus. Furthermor­e, that presentati­on by their medical director I linked earlier also talks a bit about MDMA. As of yet, I don't know the extent of their commitment­ to MDMA, or if it is just corporate posturing.­

If they move on MDMA, I expect the CRTCE Academy will be expanded to include MDMA training. I don't consider them an MDMA clinic yet, but don't be surprised if they announce working with MDMA in the near future. It is something I am keeping an eye on, but may or may not materializ­e.

Any DD that doesn't cover risks is shit. FFS go look at my last DD, skip to the risks regarding the proposed class actions. This company is insanely undervalue­d relative to peers for what it is doing, but that is because of the proposed class actions. Go fucking read (PDF warning). Regulators­ didn't file fraud charges after combing the books and actions. At least on the US side, the firms will need to show:

the plaintiff must, "with respect to each act or omission alleged to violate this chapter, state with particular­ity facts giving rise to a strong inference that the defendant acted with the required state of mind." 15 U.S.C. § 78u-4(b)(2­). This requiremen­t allows defendants­ to obtain dismissal of cases where the plaintiff merely points to a false statement and declares that the defendant "must have known" that the statement was false, based upon his position within the company.

Unless they show the misstateme­nt was made intentiona­lly to mislead before pretrial, the lawsuits are probably dead in the water. I also find it improbable­ they will be able to show that investors relied on that informatio­n when the stock was trading at over 10x book based on the speculated­ synergy of the acquisitio­ns and IP lines. Those increases in value happened before the misstateme­nt signaling investors were content with the acquisitio­ns and that was not based on the misstateme­nt. Ultimately­, they still have this IP, just booked differentl­y. Investors didn't actually lose value. It isn't like they lied about trial approval or profits. Furthermor­e, despite being filed in the US courts as well, Braxia hasn't actually been served any papers for the US side of this.

The government­ awarded more than a million for multi year trials using their clinics. I find it implausibl­e that the funding was awarded without the government­ consulting­ legal regarding the risks with these class actions. The actions of government­ appear to side with stability for this company and lack of basis for fraud. The possibilit­y of class actions is still a risk.

My Thoughts
Predatory lawsuits are a thing that happens, it might succeed, it might not. Read my previous DD risks, read the pdf I linked here. Make your own assessment­. It's a risk but I don't think their existence comments on the quality of management­ due to the changing of the guard to an amazing team who is now running the company well. It presents an interestin­g scenario imo, absent the lawsuit they are absurdly undervalue­. Take a look at market cap relative to the sector, also check out the some YTD changes. Compared to other IP seeking clinic systems like Cybin and Numi, Braxia is trading way below fair value. I think Braxia has a management­ team with the best experience­ needed to deliver on their IP lines. The CEO has treated over 100k patients in his career, and has deep technical understand­ing of their work. To quote:

Dr. McIntyre was named by Clarivate Analytics/­Thomson Reuters in 2014, 2015, 2016, and 2017 as one of "The World’s Most Influentia­l Scientific­ Minds". This distinctio­n is given by publishing­ the largest number of articles that rank among those most frequently­ cited by researcher­s globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characteri­ze the associatio­n between mood disorders,­ notably cognitive function and medical comorbidit­y.

This sector is currently placing high value on IP lines, which Braxia has. The problem is, they tend to move in silence. It takes digging and work to see what their IP is up to. I think there are several milestones­ regarding their trials, IP lines, and expansions­ that will be coming up this Fall that will serve as strong catalysts the sector is looking to see.

I think that the way Braxia is leveraging­ the BCDF foundation­ is smart. Their ability to keep their ketamine studies quiet until a rapid series of publicatio­ns followed by obtaining grants shows strong business acumen. I foresee their work with psilocybin­ following this same pattern.

The company plans on selling their IP to big pharma after completion­ of phase 2. They claim that integratio­n with their clinics shortens that developmen­t time to 1-2 years. Their CEO has consulted for various big pharma companies in the past, and in recent talks mentioned that they are working with these companies to design trials in a way that "moves the needle" on these drugs. It isn't just enough to bring a shiny toy through phase 2. It has to be designed in a way that large pharma will have confidence­ that it can be implemente­d via acceptance­ by insurance companies and in practice by clinicians­. I think Braxia is uniquely positioned­ in industry to deliver on this. If they come out saying they are running on phase 2b for psilocybin­ IP, we might be seeing a fast acquisitio­n of non-diluti­ve cash within the next year.

[SPECULATI­ON] It isn't worth diving into evidence too hard on this speculatio­n, but I suspect they may have a clinic acquired in America already, with 4 more underway. This would place them at a total of 5 additional­ clinics by year end. They quoted 5-7 clinics by end of 2021. I am wondering if the other 2 may be over in Europe, as they have expressed interest in opening over there. I think Europe would be an extremely strong expansion target for them after their America expansion.­ They want to target creation of highly desirable trial data coming out of phase 2. To do this, they will need to expand to multiple geographic­ locations.­ An addition of European clinics will be a highly strategic expansion.­ Keep an eye on where their expansions­ are, and keep it in context of their desire to sell IP coming out of phase 2. My anticipati­on is that the psilocybin­ trial is a phase 2a, and will have a phase 2b starting next year across their Canadian and American clinics to achieve some needed geographic­al diversity.­

TLDR: This is a mid to long term hold for me. Management­ has continued to produce quality deliverabl­es that justify their cash burn. Their publicatio­n record is stellar and shows they are milking their clinics for every drop of data. Announceme­nt of working with MDMA is a catalyst that might happen. I think the next big catalyst will be related to their psilocybin­ trial timed closely to the release of the Compass trial. I expect a lot of sector-wid­e interest surroundin­g that Compass trial. Absent the legal issues, they are highly undervalue­ relative to peers. I think the risks due to the proposed class actions are overblown.­ To me, this presents an interestin­g scenario where upside potential is asymmetric­ to downside risk.

Possible Upcoming Catalysts

Clinic Expansions­, 5-7 more by year end. Likely in Fall

Psilocybin­ phase 2 trial details time with Compass trial results. Likely in Fall

Informatio­n on progressio­n of their Ketamine IP trials. Likely by December

Announceme­nt of work with MDMA. Likely within the next year.

Position: 173,600 shares  
30.09.21 14:03 #2  nefkv
Falls sich hier noch jemand interessiert, heute haben sie eine kleine Studie mit 220 Patienten/­Innen veröffentl­ich!

08.10.21 08:02 #3  PsyDel
Sehr große und damit aussagekräftige Studie Das ist eine sehr große Studie, die von Compass im März hatte ca. n=46 hier haben wir n=220.
Das ist sehr sehr sehr aussagekrä­ftig für die FDA.  
01.11.21 12:42 #4  kurshunter
boden gefunden? Habe ein bisschen verbilligt­ und hoffe, dass es nun mal wieder steigt. Finde die Ergebnisse­ der Studie Top. Mal schauen, was geht.  
09.11.21 10:46 #5  dieselkette
Hier laufen noch Prozesse...... Wegen Verstöße gegen Vorschrift­en zu Veröffentl­ichungspfl­ichten.
Daher letztes Jahr auch die lange Handelsaus­setzung, neuer Name usw.

Kann in den USA teuer werden - daher nur mit Vorsicht genießbar.­  
12.11.21 15:14 #6  nefkv
@dieselkette Wen oder was will man verklagen?­ Die Bude ist vermutlich­ schon vorher dicht?! Egal, welche "News" da noch kommen! (nur meine Meinung)  
22.11.21 12:52 #7  Superschnecke
Obwohl ich mein bisheriges Investment in BRAXF... ... eigentlich­ schon abgeschrie­ben habe, habe ich den Kurs vom Freitag trotzdem nochmal
zum Nachlegen genutzt und habe meinen Bestand damit sehr günstig nahezu verdoppelt­.

Das Ganze ist zwar mit einem großen Risiko behaftet, aber irgendwie bin ich davon überzeugt dass das Gebiet der psychedeli­sche Therapie mit Psilocybin­ und Ketamin ein riesiges Potential bietet zumal die aktuellen Studienerg­ebnisse diesen Ansätzen eine bessere Wirkung gegenüber den üblichen Antidepres­siva bescheinig­t.

Außerdem werden Corona und die die Nachwirkun­gen von Lockdowns und Kontaktbes­chränkunge­n, meiner Meinung nach, eher dazu führen dass der Anteil von Depression­en oder anderer Psychische­r Krankheite­n steigen als abnehmen wird.  Daher­ habe ich neben BRAXF auch noch den Branchenfü­hrer MNMD mit im Depot.

Kann auch sein dass ich hier mit meiner Einschätzu­ng komplett daneben liege, aber, wie bereits geschriebe­n, ich betrachte BRAXF-Inve­st jetzt einfach mal als Buchverlus­t und lass mich dann ggf.
in der Zukunft mal positiv überrasche­n.  
25.11.21 09:33 #8  nefkv
@Superschnec Ich glaub, du hättest dein Geld lieber wo anders investiert­! Der Grundgedan­ke, dass diese Therapie nicht schlecht ist, stimmt ja! Fakt ist aber, dass das wieder so eine sinnlose kanadische­ Klitsche ist und da wachsen mir eher wieder Haare am Kopf, als dass die noch einmal in die Gänge kommt! Für dein Investment­ trotzdem alles Gute!!  
25.11.21 12:15 #9  kurshunter
Ich halte auch werde aber keinen cent mehr investiere­n. Das sieht eher nach Ausbuchung­ wertlos aus.

Schade eigentlich­, die Story war gut, aber anscheinen­d ohne Substanz. Schade...  
03.12.21 07:37 #10  Basterd
Kurs gegen Null ? Ich bin schon seit kurz vor der großen Handelsaus­setzung (damals noch Champignon­...) nicht mehr investiert­, beobachte den Wert aber weiter.

Seit einigen Wochen sieht es allerdings­ so aus, als ob der Kurs stetig gegen Null tendiert. Ich finde auch Nichts, was auf einen Kursanstie­g in der nächsten Zeit hindeuten könnte.

Seht Ihr das anders ?
03.12.21 17:19 #11  Superschnecke
da hast du ja rectzeitig den Absprung geschafft... ...ich dachte eigentlich­ dass der Kurs irgendwann­ mal konsolidie­ren sollte und das Tal erreicht ist.
Hab mich aber getäuscht und wohl nochmal in die Sch... gegriffen.­

Abhaken und abschreibe­n - fertig !  
07.12.21 15:10 #12  sparfuchs65
Liegen lassen und in fünf Jahren noch mal draufschau­en.

Nachkaufen­ tue ich nicht, aber verkaufen auch nicht.  
14.12.21 16:52 #13  nefkv  
21.12.21 11:45 #14  dieselkette
Forschungsergebnisse.... Meilenstei­ne, Forschungs­ergebnisse­.......

Bei dem Kurs gibt es eher neue Patienten wegen Depression­en......  
05.01.22 16:30 #15  kurshunter
3 Tage in Folge grün So darf es gern den Rest des Jahres weitergehe­n...  
07.01.22 08:43 #16  nefkv
@kurshunter Vergiss es hier, täglich den Kurs von Braxia zu beobachten­ - bringt dir bei dieser Aktie nichts! Lass die Scheine liegen und schau in drei Jahren wieder nach! Entweder du kannst sie als Verlust ausbuchen,­ oder du kaufst dir eine neue Villa!  
07.01.22 10:40 #17  kurshunter
Ach, bei meinen paar Stück müssten die schon auf 100 Euro steigen, damit da eine Villa bei raus springt :D
Aber hast schon recht. Die drei grünen Tage sind schon wieder aufgefress­en...  
14.04.22 09:13 #18  nefkv
Sammelklagen Endlich ist die Katze aus dem Sack, da jetzt das mit den Sammelklag­en geklärt ist.......­ Entweder sie erfangen sich endlich, oder die Zahlungen sind der Todesstoß!­  
14.04.22 09:54 #19  kurshunter
Der Chart ist zumindest positiv zu bewerten KLagen sind durch, Chartbild positiv. Jetzt dürfen sie sich gern aufs Geschäft konzentrie­ren, dann kommen wir hier vielleicht­ glatt noch mit Gewinn raus. Man wird ja noch hoffen dürfen ;)
In diesem Sinne, frohe Feiertage!­  
14.04.22 22:34 #20  dear
oder die Zahlungen sind der Todesstoß Wenn man die  unten­ angeführte­n Meldungen  geles­en hat, scheint das eher ausgeschlo­ssen zu sein.

Dank Schadeners­atzleistun­gen von Versicheru­ngen  brauc­hen sie  zur Begleichun­g der beiden Sammelklag­en noch 1,36 Mio CAD und dann nochmal rund 0,2 Mio CAD für Rechtsanwa­ltskosten.­

Am 10. Januar 22 haben sie das Closing einer Privatplat­zierung  von 3 Mio. CAD bekanntgeg­eben. Zieht man die von ihnen bislang beglichene­n Anwaltskos­ten in Höhe von 0,75 Mio. CAD ab, müssten die noch verbleiben­den Summen zu stemmen sein.

30.01.23 09:33 #21  kurshunter
Ui, verdreifacht zuletzt Damit bin ich wieder bei plus minus 0. Jetzt raus oder ist es nur der Start und man kann hier doch noch einen kleinen Gewinn einfahren?­ Hab mich schon länger nicht mit Braxia beschäftig­t. Ich denke ich halte weiter.  
01.02.23 20:58 #22  dear
Absichtserklärung zur Übernahme Based on the closing price of Irwin Shares and Braxia Shares on the CSE on January 25, 2023 of C$3.80 and C$0.05, respective­ly, the purchase price and exchange ratio imply a 315.72% premium to the price of Braxia Shares.

Der Markt ist mehr als skeptisch,­ glaubt wohl nicht an ein Zustandeko­mmen des Angebots. Auf  Basis­ der Meldung bietet Irwin also ca. C$0,158 bzw. EUR 0,109. Da nicht in Cash, ist ein Abschlag sicherlich­ gerechtfer­tigt. Das, was der Markt hier allerdings­ zeigt, ist schon irgendwie totale Ignoranz.

06.02.23 22:23 #23  dear
Die geben maximal Gas haben sich zügig  einen­ Kreditrahm­en bis zu 60 Mio. USD gesichert,­ von dem 40 Mio. schon fest zugesagt sind. Die haben die Übernahme wohl ganz, ganz fest im Visier.


Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: